Cargando…

Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma

Asparaginase/pegaspargase containing regimens combined with radiotherapy are highly effective and considered the cornerstone of localized Natural killer/T-cell lymphoma (NKTL) treatment. However, these chemotherapy regimens inevitably cause relatively high incidence of treatment-related adverse even...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Peng, Wang, Yu, Yang, Hang, Chen, Cui, Nie, Man, Sun, Xiao-Qing, He, Xiao-Hua, Huang, Kang-Ming, Huang, Jia-Jia, Li, Zhi-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882643/ https://www.ncbi.nlm.nih.gov/pubmed/35237257 http://dx.doi.org/10.3389/fimmu.2022.766200

Ejemplares similares

Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III study
por: Zhong, Huijuan, et al.
Publicado: (2023)

A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type
por: Xu, Peng-Peng, et al.
Publicado: (2017)

P1119: CAMRELIZUMAB PLUS LOW-DOSE APATINIB AND PEGASPARGASE FOLLOWED BY RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II NATURAL KILLER/T-CELL LYMPHOMA: A PROSPECTIVE MULTICENTER SINGLE-ARM STUDY
por: Zhi-Ming, LI, et al.
Publicado: (2023)

Treatment of Children with Advanced-Stage Lymphoblastic Lymphoma with Pegaspargase
por: Yu-tong, Zhang, et al.
Publicado: (2014)

The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type
por: Zhang, Lei, et al.
Publicado: (2016)

Pegaspargase Combined with Concurrent Radiotherapy for Early‐Stage Extranodal Natural Killer/T‐Cell Lymphoma, Nasal Type: A Two‐Center Phase II Study
por: Wang, Hua, et al.
Publicado: (2020)

Development of a Lyophilized Formulation of Pegaspargase and Comparability Versus Liquid Pegaspargase
por: Faschinger, Alexander M., et al.
Publicado: (2019)

A Prospective Phase II Study of Pegaspargase-COEP Plus Radiotherapy in Patients With Newly Diagnosed Extra-Nodal NK/T-Cell Lymphoma
por: Hu, Shaoxuan, et al.
Publicado: (2022)

Utility of baseline, interim and end-of-treatment (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase
por: Chang, Yu, et al.
Publicado: (2017)

Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma
por: Wang, Jing-hua, et al.
Publicado: (2016)

Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149
por: Zhang, Lei, et al.
Publicado: (2016)

Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
por: Heo, Young-A., et al.
Publicado: (2019)

Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in treatment of advanced extranodal NK/T-cell lymphoma
por: Fu, Ruiying, et al.
Publicado: (2023)

Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA
por: Liang, J-H, et al.
Publicado: (2017)

PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study
por: Du, Xin-Xing, et al.
Publicado: (2022)

Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma
por: Huang, Jia-Jia, et al.
Publicado: (2013)

The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer
por: Zheng, Wubin, et al.
Publicado: (2022)

Expression of PD-L1 on Monocytes Is a Novel Predictor of Prognosis in Natural Killer/T-Cell Lymphoma
por: Zhang, Xue-wen, et al.
Publicado: (2020)

Pegaspargase Induced Hypertriglyceridemia Resulting in Severe Fatal Pancreatitis
por: Vyas, Neil, et al.
Publicado: (2015)

Correction to: Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
por: Heo, Young-A., et al.
Publicado: (2019)

VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma
por: He, Hai-Xia, et al.
Publicado: (2021)

A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T‐cell lymphoma, nasal type: a multicenter trial in Northwest China
por: Liang, Rong, et al.
Publicado: (2016)

Consolidative treatment after salvage chemotherapy improves prognosis in patients with relapsed extranodal natural killer/T-cell lymphoma
por: Nie, Man, et al.
Publicado: (2016)

Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study
por: Liu, Tao, et al.
Publicado: (2018)

Vaccines against SARS‐CoV‐2 are safe to administer in patients with antibodies to pegaspargase
por: Swanson, Hope D., et al.
Publicado: (2022)

Gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy with sandwiched radiotherapy in the treatment of newly diagnosed stage IE/IIE extranodal natural killer/T‐cell lymphoma, nasal type
por: Tian, Shu, et al.
Publicado: (2019)

Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Epithelial Ovarian Cancer: A Retrospective Study
por: Li, Xiao-Yuan, et al.
Publicado: (2022)

R-split-EPOCH plus high dose methotrexate in untreated diffuse large B cell lymphoma with MYC rearrangement or double expression of MYC and BCL-2
por: Sun, Peng, et al.
Publicado: (2021)

Serum C-Reactive Protein (CRP) as a Simple and Independent Prognostic Factor in Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
por: Li, Ya-Jun, et al.
Publicado: (2013)

Perforated jejunitis in a child with acute lymphoblastic leukemia treated with pegaspargase
por: Tang, Elizabeth R., et al.
Publicado: (2018)

Anlotinib Combined with Cranial Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Retrospectively, Control Study
por: He, Zelai, et al.
Publicado: (2021)

Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma
por: Cai, Jun, et al.
Publicado: (2020)

Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
por: Yan, Zheng, et al.
Publicado: (2020)

anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells
por: Liu, Shaochuan, et al.
Publicado: (2020)

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma
por: Wang, Jing-hua, et al.
Publicado: (2016)

S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine
por: Zhou, Zhiyuan, et al.
Publicado: (2016)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
por: Lu, Suying, et al.
Publicado: (2022)

Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma
por: Liu, Xin, et al.
Publicado: (2019)

P1150: A PROSPECTIVE PHASE II CLINICAL TRIAL USING CHIDAMIDE, TISLELIZUMAB, AND PEGASPARGASE IN COMBINATION WITH RADIOTHERAPY AS FIRST-LINE TREATMENT IN STAGES I/II OF EXTRANODAL NK/T-CELL LYMPHOMA
por: Zhou, Hui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ku5ra42tlunnc8gm9c6cf9br42